Vermillion, Inc. a molecular diagnostics company, announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent entitled “Biomarkers for Peripheral Artery Disease” (PAD) The patent claims cover the biomarker alpha1beta glycoprotein and biomarker combinations that include alpha1beta glycoprotein for the diagnosis of PAD.

“This will be our third patent for biomarkers that can be used for the diagnosis of PAD and represents a critical asset for Vermillion. Expanding our intellectual property portfolio helps protect the potential significant value of our PAD program as we progress our clinical studies,” said Gail S Page, CEO of Vermillion.

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients.